Lead Product(s) : Iadademstat,Atezolizumab,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Doses First Patient in Lung Cancer Trial of Iadademstat with Checkpoint Drugs
Details : ORY-1001 (iadademstat) is a highly selective inhibitor of the epigenetic enzyme LSD1. It is being investigated in patients with extensive-stage small cell lung cancer.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 15, 2025
Lead Product(s) : Iadademstat,Atezolizumab,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABTL0812,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
AbilityPharma Raises €7M to Advance Phase 2b ABTL0812 for Metastatic Pancreatic Cancer
Details : AbilityPharma to obtain financing for the clinical development of ABTL0812 in combination with folfirinox. It is being evaluated in Phase I/II clinical trial studies for Metastatic Pancreatic Cancer.
Product Name : ABTL0812
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 03, 2024
Lead Product(s) : ABTL0812,Fluorouracil,Calcium Folinate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CTI Life Sciences
Deal Size : $7.6 million
Deal Type : Financing
Lead Product(s) : Iadademstat,Durvalumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ORYZON Receives FDA Clearance for Iadademstat Plus Checkpoint Inhibitors Trial
Details : ORY-1001 (iadademstat) is a selective LSD1 inhibitor investigated with immune checkpoint inhibitors in extensive disease small cell lung cancer patients.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2024
Lead Product(s) : Iadademstat,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : IDP-121
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : IDP-121 is a potent, selective peptidomimetic that acts by simultaneously obstructing the formation of the cMyc/Max complex while also augmenting cMyc degradation through the intrinsic cellular machinery.
Product Name : IDP-121
Product Type : Peptide
Upfront Cash : Inapplicable
October 26, 2023
Lead Product(s) : IDP-121
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Iadademstat
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A first in man Phase I/IIa clinical trial with iadademstat in refractory and relapsed acute leukemia patients demonstrated safety and good tolerability of the drug.
Product Name : ORY-1001
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 13, 2021
Lead Product(s) : Iadademstat
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Omomyc
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Peptomyc’s OMO-103, Has Obtained Approval for First-in-Human Phase I
Details : Peptomyc has received approval from the Spanish Agency of Medicines and Medical Devices for conducting clinical trials in Spain (AEMPS), to initiate the first-in-human Phase I/II clinical trial with its first compound - a disruptive Myc inhibitor, Omomyc...
Product Name : OMO-103
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2021
Lead Product(s) : Omomyc
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable